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19% (p	 <	0.0001,	 log-	rank	 test)	 and	11%	 (p	 =	0.007)	when	 fed	 at	 14.4	ppm	 start-
ing	at	16	and	20	months,	respectively.	90th	percentile	lifespans	were	extended	7%	
(p	=	0.004,	Wang–	Allison	test)	and	5%	(p	=	0.17).	Body	weights	were	reduced	about	
20%	after	 starting	 the	17aE2	diets.	 Four	other	 interventions	were	 tested	 in	males	
and	females:	nicotinamide	riboside,	candesartan	cilexetil,	geranylgeranylacetone,	and	
MIF098. Despite some data suggesting that nicotinamide riboside would be effective, 
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1  |  INTRODUC TION
Each year, the Interventions Testing Program (ITP; http://www.nia.
nih.gov/resea	rch/dab/inter	venti	ons-	testi	ng-	progr	am-	itp)	 tests	 the	
effects of a variety of compounds on lifespan in a genetically hetero-
geneous	mouse	model	(UM-	HET3),	the	first-	generation	offspring	of	
the	CByB6F1	x	C3D2F1	cross,	to	produce	a	diverse	heterogeneous	
population that is reproducible across time and place (Roderick, 
1963).	ITP	studies	are	conducted	simultaneously	at	The	University	
of	 Texas	 (UT),	 University	 of	 Michigan	 (UM),	 and	 The	 Jackson	
Laboratory	(TJL)	in	Bar	Harbor,	ME.	Details	of	the	ITP	design	have	
been published (Harrison et al., 2009; Harrison et al., 2014; Harrison 




age. The data in this paper come from the initial survival cohorts, and 
thus focus on lifespans, which integrate all biological effects that 




The interventions for the present study were chosen for the fol-
lowing reasons:
(a)	17-	α-	estradiol	 (17aE2)	 is	a	 relatively	 “non-	feminizing”	estro-
gen which shows reduced activation of classical estrogen recep-
tors	compared	with	17-	β-	estradiol	 (Anstead	et	al.,	1997).	Harrison	





median male lifespans increased 19% (p	<	0.001);	the	90%	lifespan	
increased 12%, but females still did not benefit. Thus, only males 
were	tested	in	the	present	study.	To	determine	whether	17aE2	treat-
ment is effective when initiated in older mice, males were treated 
beginning at 16 or 20 months of age, choosing middle age, and early 











Trammell,	 Schmidt,	 et	 al.	 (2016)	 reported	 that	 in	mice	 and	hu-
mans	NR	is	bioactive	when	given	by	mouth,	unlike	most	other	nico-
tinamide	derivatives.	In	2016b,	they	reported	that	NR	improved	liver	
function and protected against diabetic neuropathy. When fed to 
C57BL/6	 J	mice	 from	10	weeks	of	 age,	NR	protects	 against	 high-	
fat	diet	(HFD)-	induced	obesity	and	promotes	oxidative	metabolism	
by	 increasing	 the	 NAD+/NADH	 ratio	 in	 muscle,	 liver,	 and	 brown	
adipose	tissue	 (Canto´et	al.,	2012).	Ryu	et	al.	 (2016)	found	that	 in-
creasing	 NAD+stores	 with	 NR	 supplementation	 improved	 muscle	
function and alleviated heart defects in a mouse model of muscu-
lar	dystrophy.	Mitchell	et	al.	(2018)	reported	that	an	NR	metabolite,	
nicotinamide, did not increase lifespan when started at 12 months 
in	C57BL/6	 J	mice	 but	 improved	 some	health	 outcome	measures.	
Due to its benefits in a variety of diseases, and reports of benefits 
in	mouse	lifespans,	NR	treatment	was	proposed	to	increase	lifespan	
in UM- HET3 mice.
c)	Candesartan	cilexetil	(CC)	is	an	angiotensin-	receptor	blocker,	
which	lowers	blood	pressure	(Ikeda	et	al.,	2006)	and	improves	car-
diovascular function and insulin sensitivity in obese, hypertensive 
patients	 (Grassi	 et	 al.,	 2003).	 Importantly,	 angiotensin-	receptor	
knockout	 increases	 lifespan	of	mice	 (Benigni	et	al.	2009).	Because	
CC	is	effective	against	age-	related	diseases,	and	sensitizes	the	body	
to insulin, and because the angiotensin- receptor knockout increases 
lifespan	of	mice,	 treatment	with	CC	was	hypothesized	 to	 increase	
lifespan.
(d)	To	maintain	good	quality	protein	in	the	body,	heat	shock	pro-
teins	 (HSPs)	 are	 vital.	 Geranylgeranylacetone	 (GGA)	 induces	 heat	
shock	 protein	 (Hsp70)	 in	mammalian	 tissues	 and	 promotes	 insulin	
sensitivity	 in	 old	mice	 (Silverstein	 et	 al.,	 2015),	 while	 van	Marion	
et	 al.	 (2020)	 showed	 that	 it	 increases	HSP	expression	 in	atrial	 tis-
sue	after	heart	 surgery.	Pride	et	 al.	 (2015)	 showed	 that	 long-	lived	
species, compared with related short- lived species within the same 
order, have elevated HSP levels in conjunction with better proteo-
stasis. To test whether treatment with an established HSP inducer 
neither it nor the other three increased lifespans significantly at the doses tested. The 
17aE2	results	confirm	and	extend	our	original	reports,	with	very	similar	results	when	
started at 16 months compared with mice started at 10 months of age in a prior study. 
The consistently large lifespan benefit in males, even when treatment is started late in 
life,	may	provide	information	on	sex-	specific	aspects	of	aging.
K E Y W O R D S
17-	α-	estradiol,	candesartan	cilexetil,	geranylgeranylacetone,	heterogeneous	mice,	lifespan,	
macrophage migration inhibitory factor, nicotinamide riboside
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tagonist	 that	 regulates	 CD44	 binding	 (Yoo	 et	 al.,	 2016).	MIF	 is	
a proinflammatory cytokine, so MIF098 reduces inflammation. 
This may include the chronic inflammation that increases with 
age,	as	suggested	by	the	finding	of	Harper	et	al.	(2010)	that	MIF-	
knockout mice live significantly longer than controls. Because it 
is orally bioavailable and shows MIF inhibitory activity in mouse 
models	 of	 hyperoxic	 lung	 injury,	 as	 well	 as	 in	 other	 diseases	
(Sauler	et	al.,	2015),	treatment	with	MIF098	was	proposed	to	in-




occurred even when the drug was not fed until late middle or early 
old	 age	 (16	 and	20	months	 of	 age,	 respectively).	 The	 range	of	 ages	
for	which	 treatment	 is	 effective	 suggests	 that	 benefits	 from	17aE2	
do not depend on effects earlier in life, such as growth alteration. 








at 16 months (p	 =	 0.004,	Wang–	Allison	 statistic);	 however,	 when	
treatment was started at 20 months, the 5% increase in the 90th 
percentile lifespan was not significant (p	=	0.17)	(Table	1;	Figure	1).	
These	data	hint	that	benefits	from	17aE2	diminish	when	treatment	
is started at 20 rather than at 16 months; however, when comparing 
the median lifespan results between the two treatment groups, no 
significant difference was detected (p	=	0.24,	log-	rank	test).
Mice were weighed every 6 months beginning at 6 months of 
age. Prior to treatment, at 6 and 12 months of age, the mean weight 











Cont_16 304 874 1047
NR 136 875 0% 0.612 1068 2% 0.99
CC 136 880 1% 0.235 1120 7% 0.092
GGA 136 894 2% 0.72 1081 3% 0.176
MIF098 136 863 −1% 0.069 1028 – 2% 0.314
Males
Cont_16 303 787 1047
17aE2	16 156 933 19% <0.0001 1120 7% 0.004
17aE2	20 159 871 11% 0.007 1103 5% 0.174
NR 156 763 −3% 0.252 1019 −3% 0.99
CC 156 820 4% 0.370 1055 1% 0.733
GGA 156 825 5% 0.720 1070 2% 0.730
MIF098 156 821 4% 0.645 1055 1% 0.99
Lifespans of ITP mice from cohort 2016.




N = number of mice tested; data were pooled, with about 1/3 of the mice from each testing site; 
see Table 2 caption for details.
Under Median lifespan: Days— median ages; % change calculated with respect to controls. 
p- value = probability that lifespans are the same as the controls using two- tailed log- rank test 
on	pooled	data	stratified	by	sites;	"removed"	mice	were	included	as	censored	(see	Experimental	
Procedures).
Under lifespan at 90th percentile: Days = age at 90th percentile, % change from control.
Wang–	Allison	p- value = probability that the proportion of live mice is the same in treated as in the 
control	group	at	the	90th	percentile	age,	evaluated	by	the	procedure	of	Wang	et	al.	(2004).
TA B L E  1 Effects	of	interventions	on	
lifespan; data pooled from the 3 sites
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of each group of mice designated for treatment was comparable to 
the weight of the group designated as the untreated control group. 
Weights	 of	 male	 mice	 started	 on	 17aE2	 at	 16	months	 decreased	
about	 20%	 by	 18	months,	 and	weights	 of	mice	 started	 on	 17aE2	
at	20	months	decreased	 about	20%	by	24	months	 (Figure	2B).	At	
24	months,	the	weights	of	both	of	the	17aE2	treatment	groups	were	
similar, and both were about 8.5 g lighter than controls (p < 0.001 in 
both	cases).
Comparing	 median	 lifespans	 across	 individual	 sites	 (Table	 2),	
starting	males	on	17aE2	diets	at	16	months	increased	lifespans	20%	
at both TJL (p	=	0.001,	 log-	rank	 test)	 and	UT	 (p	<	0.0001),	with	a	
16% increase at UM (p	=	0.06).	Starting	17aE2	diets	at	20	months	
increased	lifespans	17%	at	TJL,	11%	at	UM,	and	5%	at	UT;	only	the	
17%	increase	was	significant	(p	=	0.02).	Comparing	median	lifespans	
within	 each	 site,	 starting	 17aE2	 treatment	 at	 16	 months	 tended	
to increase lifespans more than starting treatment at 20 months 
(Table	2),	 although	 the	difference	 reached	 significance	only	 at	UT	
(p	=	0.003).
Lifespans	for	pooled	data	(across	the	three	sites)	were	not	signifi-
cantly affected in UM- HET3 males or females fed diets with 1,000 ppm 
nicotinamide	riboside	(NR),	30	ppm	candesartan	cilexetil	(CC),	600	ppm	
geranylgeranylacetone	(GGA),	or	240	ppm	MIF098	(Table	1,	Figure	3).	
Site- specific effects on lifespans were also not significant, although the 
site-	specific	data	sets	had	far	less	statistical	power	(Table	2).	NR	led	to	
a marginally significant increase in female lifespan at one site, but this 
was balanced by a marginally significant decline in female lifespan at 







MIF098 were similar to weights in controls.
As	detailed	in	the	Experimental	Procedures,	NR,	CC,	GGA,	and	
MIF098 were each present in the diet pellets at about the amounts 
expected.	Nicotinamide	was	detected	in	serum	at	the	following	lev-
els (mean ± SD	[n],	ng/ml):	controls	105	±	46	(n	=	19)	and	NR-	treated	
401 ± 212 (n	=	31),	with	males	and	females	pooled	because	their	re-
sults were similar. Treated mice had significantly more nicotinamide 
(p	<	0.0001	by	Mann–	Whitney	test).	No	NR	was	detected,	but	the	






sue),	and	 leg	muscle	 from	6-	 to	10-	month-	old	UM-	HET3	mice	 fed	
control	or	1,000	ppm	NR	diet	for	6–	6.5	weeks,	with	3	males	and	4	
females per group. The most interesting positive finding was lower 
levels (p	=	0.004)	of	nicotinamide	in	cortex	(though	not	liver)	of	NR-	
treated	mice.	NR-	treated	mice	 also	 had	 lower	NR	 levels	 in	 cortex	
(but	not	in	liver),	compared	with	controls	(p	=	0.03).	The	ratio	of	NAD	
to	NADH	in	the	cortex	was	lower	in	NR-	treated	males	(p	=	0.012).	
These results are preliminary, because numbers of mice tested were 
low, and the diets were only fed to young mice for 6 weeks.
Candesartan	(but	not	CC)	was	found	in	plasma	of	all	four	female	
and	three	male	UM-	HET3	mice	fed	CC	for	8	weeks:	values	(ng/ml)	
for the females were 25, 44, 19, and 49; values for the males were 
40, 26, and 23. The four female and three male controls all had less 
than	the	5	ng/ml	detection	limit	of	CC.	In	mice	receiving	dietary	GGA	
and MIF098, amounts were below detection limits in serum (1 µg/ml 
and	15	ng/ml,	respectively).
F I G U R E  1 Effects	of	17aE2	on	lifespan	curves	showing	male	
control	and	males	fed	17aE2	diets	started	at	16	months	or	at	
20 months of age. Table 1 gives more details on these lifespans
F I G U R E  2 Effects	of	interventions	on	
body	weights.	Panel	A	shows	females,	
and Panel B shows males. Weights are 




were fed from 8 months of age, while 
GGA	was	fed	from	9	months	of	age
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3  |  DISCUSSION
Earlier	 ITP	 studies	 found	 that	 17aE2	 treatment,	 initiated	 at	
10 months of age, increased lifespan in UM- HET3 males but had no 




was significantly increased in both treatment groups compared with 







vation of the mice are standardized across sites and time; thus, results 








found a 12% increase when treatment was started at 10 months; in 
the	current	study,	 the	90th	percentile	 lifespan	 increased	7%	when	
treatment	was	started	at	16	months	(Table	1).	Thus,	17aE2	joins	rapa-




started in middle age, it still works, but only about ½ as well as it does 
when	it	starts	in	young	mice	(Harrison	et	al.,	2019).
The	dramatic	 sexual	 dimorphism	 in	 response	 to	17aE2	 treat-
ment may help elucidate aspects of the mechanism by which 




changeDays % change p- value Days % change p- value Days % change p- value
Females
Cont_16 883 858 882
NR 968 10% 0.040 799 −7% 0.033 857 −3% 0.335 0%
CC 896 1% 0.124 867 1% 0.371 876 −1% 0.413 0%
GGA 905 2% 0.461 916 7% 0.152 892 1% 0.930 3%
MIF098 895 1% 0.874 836 −3% 0.084 866 −2% 0.347 −1%
Males
Cont_16 752 826 799
17aE2	16 906 20% 0.006 943 14% 0.110 955 20% 0.0001 18%
17aE2	20 896 19% 0.027 900 9% 0.160 840 5% 0.444 11%
NR 757 1% 0.968 852 3% 0.398 712 −11% 0.019 −3%
CC 826 10% 0.035 866 5% 0.487 770 −4% 0.689 4%
GGA 787 5% 0.729 914 11% 0.156 801 0 0.875 5%
MIF098 829 10% 0.228 810 −2% 0.721 826 3 0.491 4%
For	each	site,	TJL	(the	Jackson	Laboratory),	UM	(University	of	Michigan),	UT	(University	of	Texas),	numbers	in	treated	groups	were	51–	54	per	site	for	
males and 44– 48 for females; numbers of controls were 99– 102 for males and 92– 116 for females.
This table lists: Group— the same as Table 1. Days = median survival in days, % change from control, and the log- rank P that the group differs from the 
controls	(Cont_16).	The	rightmost	column	shows	the	average	(mean)	of	the	changes	in	median	lifespan	across	the	three	sites.
F I G U R E  3 Lifespan	curves	of	controls,	
and the 4 interventions without effects/. 
Panel	A	shows	females,	and	Panel	B	
shows males. Data are from the same mice 
whose lifespans are shown in Table 1
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age were 14%– 18% lighter than controls at 12, 18, and 24 months 
yet lifespans only increased in males (Strong et al., 2016, Figure 1, 




both male and female mice (Harrison et al., 2009, 2014; Miller et al., 
2011,	2014).	Thus,	the	male-	specific	lifespan	benefit	of	17aE2	con-
trasts with other treatments that produce comparable benefits in 
both	sexes,	making	this	model	valuable	for	investigation	of	sexually	
dimorphic, and potentially novel, mechanisms of aging.
Garratt	 et	 al.	 (2017,	 2018)	 evaluated	 effects	 of	 17aE2	 feeding	
on metabolic parameters in mature adult UM- HET3 mice of both 
sexes.	In	mice	started	on	17aE2	at	4	months	of	age,	and	euthanized	
at	12	months	of	age,	only	intact	(i.e.,	non-	castrated)	males	showed	
increased insulin sensitivity and improved glucose tolerance, en-
hanced	hepatic	mTORC2	signaling,	increased	Akt	activity,	and	phos-
phorylation	of	FOXO1a.	Females	and	castrated	males	did	not	show	
these changes, while ovariectomized females showed some of the 
benefits.	Using	mice	treated	at	the	same	ages,	Garratt	et	al.	(2018)	
found changes in liver amino acids, and urea cycling, in untargeted 
metabolomic analyses; these changes also were specific to intact 
males.	If	testicular	hormones	play	an	important	role	in	lifespan	ex-
tension	when	17aE2	is	given	at	10–	20	months	of	age,	perhaps	the	







ing this hypothesis by comparing lifespans in male and female mice 
given diets containing estriol.
Strong	et	al.	(2016)	noted	that	17aE2	at	the	standard	14.4	ppm	
dose reduced body weights in females and altered uterine weights 
in	 ovariectomized	mice.	 Thus,	 17aE2	 is	 partially	 active	 in	 females,	
so the absence of an effect on female lifespan is not because bio-
availability is entirely absent. These observations support the idea 
that	testicular	hormones	play	an	important	role	in	lifespan	extension	
by	17aE2.	Interestingly,	the	wide	range	of	cancers	that	cause	most	
deaths in UM- HET3 mice (Harrison et al., 2014; Lipman et al., 2004; 
Miller	&	Chrisp,	 2002)	most	 likely	 are	 postponed	 by	 17aE2	 to	 in-
crease lifespan in males.
Stout	 et	 al.	 (2017)	 reported	 that	 14.4	 ppm	 17aE2	 alleviates	
age- related metabolic and inflammatory dysfunction in 18- or 








synthesis	 rates	 expected	 with	 lifelong	 40%	 DR.	 Using	 RNA-	seq,	
Tyshkovskiy	 et	 al.	 (2019)	 found	 feminizing	 effects	 with	 most	 of	
the	 anti-	aging	 candidate	drugs	 they	 tested,	 increasing	RNAs	 char-
acteristic	of	 females	and	decreasing	RNAs	characteristic	of	males.	
Interestingly,	 the	exception	was	17aE2.	 It	might	be	 informative	 to	
feed	17aE2	to	young	or	middle-	aged	mice	and	see	how	quickly	the	
RNA	profile	is	modified	to	resemble	that	seen	in	mice	given	17aE2	
for most of their lives.
None	of	the	other	four	drugs	tested	in	the	2015	cohort,	that	is,	
NR,	CC,	GGA,	 and	MIF098,	 led	 to	 lifespan	 improvement	 in	 either	
sex.	As	reviewed	in	the	introduction,	in	many	species,	total	NAD	lev-
els	decline	with	age,	increasing	NAD	levels	benefits	many	physiolog-
ical systems in mice and men, and a small increase in mouse lifespan 
was	reported.	Our	finding	that	NR	has	no	effect	on	lifespan	in	the	
genetically variable mice that best model the human population is 
thus a surprise. In fact, the two points of most interest in this paper 
are	that	17aE2	is	effective	when	given	later	in	life,	and	that	NR	has	
no effect on lifespan.
Each	drug	was	detectable	in	food	pellets,	and	metabolites	of	NR	
and	CC	were	detected	in	plasma	of	treated	mice.	While	it	is	possible	
that one or more of these drugs might have led to health benefits if 
used at a different dose, or in another stock of mice, or if started or 
stopped at a different age, the most plausible interpretation is that 
none of the drugs slows aging or prevents disease in a genetically 
heterogeneous mouse population.
Lifespan studies of the ITP demonstrate that, when following 
precise	 standards,	 mouse	 lifespan	 can	 be	 reproducibly	 extended	
by drugs in the diet (Harrison et al., 2009, 2014, 2019; Miller et al., 
2011,	2014;	Miller,	Harrison,	et	al.,	2020;	Strong	et	al.,	2008,	2016).	
Positive	results	are	important,	as	showing	here	that	17aE2	is	benefi-
cial when started later in life. But negative results are also important, 
as	showing	here	that	NR	failed	to	increase	lifespan.
4  |  E XPERIMENTAL PROCEDURES
4.1  |  Mouse production, maintenance, and 
estimation of lifespan
UM- HET3 mice were produced at each of the three test sites as pre-





each site, breeding mice were fed LabDiet® 5008 mouse chow (PMI 
Nutritional	 International,	 Bentwood,	 MO).	 As	 soon	 as	 mice	 were	
weaned, they were fed LabDiet® 5LG6 distributed to the test sites 
from the same batch. Males were initially housed 3 per cage, while 
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females were housed 4 per cage; numbers per cage declined as mice 
died. Figure 4 shows that lifespans for both female and male controls 
were similar at all 3 sites.
Details of the methods used for health monitoring were pro-
vided previously (Harrison et al., 2009; Miller et al., 2011; Strong 
et	al.,	2008).	In	brief,	each	of	the	three	colonies	was	evaluated	four	
to	twelve	times	each	year	for	infectious	agents.	All	such	surveillance	
tests were negative for pathogens at all three sites throughout the 
entire study period.
4.2  |  Removal of mice from the 
longevity population
Mice were removed from the study because of fighting or accidental 
death	(e.g.,	during	chip	implantation)	or	chip	failure,	or	because	they	
were	used	for	another	experimental	purpose.	For	log-	rank	survival	
analyses, all such mice were “censored,” that is, treated as alive at 
the date of their removal from the protocol and lost to follow- up 
thereafter. These mice were not included in calculations of median 
longevity. For the mice in Table 1, % males removed: control, 9%; 
17aE2-	16,	 3%;	 17aE2-	20,	 10%;	NR,	 7%;	CC,	 12%;	GGA,	 13%;	 and	
MIF098, 6%. Most of these males were removed because of fight-
ing.	Fewer	females	were	removed:	control,	0.3%;	NR,	1.5%;	CC,	3%;	
GGA,	0;	and	MIF098,	0.
Thus, mice removed from the longevity population were included 
in	log-	rank	test	calculations.	The	question	as	to	whether	removal	is	ran-
dom does not apply, since no mice were removed for other purposes. 
The	 statistical	 approach	 used	 is	 the	 usual	 Kaplan–	Meier	 calculation,	
based on the log- rank test, in which mice that do not die a natural death 
(typically	because	of	removal	for	humane	reasons)	are	treated	as	known	
to be alive at the date of removal, with unknown date of death.
4.3  |  Estimation of age at death (lifespan)
At	UM	and	UT,	mice	were	examined	daily	for	signs	of	ill	health	from	
the	 time	 they	 were	 set	 up	 in	 the	 experiment.	 At	 TJL,	 mice	 over	
500	days	of	 age	were	 examined	daily	 and	 twice	 a	 day	once	 they	
were marked as ill. Mice were euthanized for humane reasons if so 
severely	moribund	 that	 they	were	 considered,	by	an	experienced	
technician, unlikely to survive for more than an additional 48 hours. 
TJL’s definitive endpoint criterion is the non- responsiveness of a 
mouse to being touched, and which is usually accompanied by one 
or more of the following: slow respiration, feeling cold to the touch, 
a hunched- up appearance with matted fur, signs of sudden weight 
loss, failure to eat and drink, prominent appearing ribs and spine, 
and sunken hips. The age at which a moribund mouse was eutha-
nized was taken as the best available estimate of its natural lifespan. 
Mice found dead were also noted at each daily inspection, giving 
the lifespan.
4.4  |  Control and experimental diets
TestDiet®,	 Inc.,	a	division	of	Purina	Mills	 (Richmond,	 IN),	prepared	
batches of radiation- sterilized LabDiet® 5LG6 food which were 
ground to powder, and to which each test substance was added, as 
well as control diets from the same large batch treated the same 
way	except	that	no	drugs	were	added	when	diets	were	ground	and	
mixed.	These	were	prepared	at	intervals	of	approximately	4	months,	
and TestDiet® shipped food from the same batch to each of the 
three	sites.	For	the	interventions	in	this	paper,	except	E2,	the	doses	
used	were	suggested	by	the	experts	who	proposed	the	compound	
and were tested in pilot studies to be sure that the mice were not 
harmed over 8 weeks.
1.	 17-	α-	estradiol	 (17aE2)	 was	 purchased	 from	 Steraloids	 Inc.	
(Newport,	 RI,	 USA)	 and	 mixed	 at	 a	 dose	 of	 14.4	 milligrams	
per	 kilogram	 diet	 (14.4	 ppm).	 Male	 mice	 were	 fed	 the	 17aE2	
diet continuously starting at either 16 or 20 months of age.
2.	 Nicotinamide	 riboside	 (NR)	 was	 generously	 provided	 by	
ChromaDex,	 1751	 S	 Fordham	 Street,	 Ste:350,	 Longmont,	 CO	
80503,	as	the	chloride	salt,	and	mixed	at	a	dose	of	1,000	mg	NR	
Chloride	 per	 kilogram	diet	 (1,000	 ppm).	Mice	were	 fed	 the	NR	









F I G U R E  4 Effects	of	site	on	control	
lifespans	in	this	cohort.	Panel	A	shows	
females, and Panel B shows males. p 
values are for median lifespans; controls 
did not differ significantly among the sites









compared against the ratios obtained by the calibration samples 





per	kilogram	diet	 (600	ppm).	Mice	were	 fed	 the	GGA	diet	 con-
tinuously	starting	at	9	months	of	age.	GGA	was	quantified	using	








fed the MIF098 diet continuously starting at 8 months of age. 
It	was	measured	using	 spiked	controls	 and	 injecting	well-	mixed	
standard	 amounts	 of	 calibrator	 and	 unknown	 in	 the	HPLC/UV.	




The 2015 cohort of UM- HET3 mice was also used to test the 
effects of canagliflozin, an inhibitor of SGLT2 (Miller, Harrison, et al., 
2020).
4.5  |  Statistical methods
Significance tests about survival effects are based upon the two- 
tailed log- rank test at p < 0.05, stratified by test site, with censored 
mice included up until their date of removal from the longevity pop-
ulation. Data from male and female mice are considered separately. 
In	statistical	tests	described	in	the	text,	P values are two- tailed and 
reported without adjustment for multiple comparisons. Statistical 
claims	related	to	maximum	lifespan	are	based	on	Wang	et	al.	(2004),	
using	the	Fisher	exact	test	to	compare	the	proportions	of	surviving	
mice, in control and test groups, at the age corresponding to the 90th 
percentile for survival in the joint distribution of the control and test 
groups. For the pooled data sets, surviving mice were enumerated 
at the 90th percentile age for each site separately, and these counts 
were	combined	for	the	overall	Fisher	exact	test.
The raw data used here are available at the Mouse Phenome 
Database	 https://pheno	me.jax.org/proje	cts/ITP1,	 The	 Jackson	
Laboratory, Bar Harbor, ME. This is supported by the Mouse 
Phenome Project and is a public data repository that provides the 
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